Cargando…
Combinatory EHMT and PARP inhibition induces an interferon response and a CD8 T cell-dependent tumor regression in PARP inhibitor-resistant models
Euchromatic histone lysine methyltransferases 1 and 2 (EHMT1/2), which catalyze demethylation of histone H3 lysine 9 (H3K9me2), contribute to tumorigenesis and therapy resistance through unknown mechanisms of action. In ovarian cancer, EHMT1/2 and H3K9me2 are directly linked to acquired resistance t...
Autores principales: | Nguyen, Lily L., Watson, Zachary L., Ortega, Raquel, Woodruff, Elizabeth R., Jordan, Kimberly R., Iwanaga, Ritsuko, Yamamoto, Tomomi M., Bailey, Courtney A., Jeong, Abigail D., Guntupalli, Saketh R., Behbakht, Kian, Gbaja, Veronica, Arnoult, Nausica, Chuong, Edward B., Bitler, Benjamin G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980116/ https://www.ncbi.nlm.nih.gov/pubmed/36865165 http://dx.doi.org/10.1101/2023.02.23.529773 |
Ejemplares similares
-
Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma
por: Watson, Zachary L., et al.
Publicado: (2019) -
99529 The Role of ATF6-Mediated Signaling in PARP Inhibitor Resistant Ovarian Cancer
por: Alexandra,, et al.
Publicado: (2021) -
Retrospective Analysis of Survival Improvement by Molecular Biomarker-Based Personalized Chemotherapy for Recurrent Ovarian Cancer
por: Kim, Youngchul, et al.
Publicado: (2014) -
Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies
por: Yélamos, José, et al.
Publicado: (2020) -
PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling
por: van Beek, Lotte, et al.
Publicado: (2021)